NCT03256981 2023-12-26
HALT
Institute of Cancer Research, United Kingdom
Phase 2/3 Unknown
Clinical Trials
9 trialsNCT06059885 2023-09-29
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Beijing 302 Hospital
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT02794337 2022-04-27
TACE-SBRT
Tata Memorial Hospital
Phase 2/3 Unknown
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03799094 2019-01-10
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
Clifford Hospital, Guangzhou, China
Phase 1/2 Unknown
NCT03624530 2018-08-10
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT02687425 2016-02-22
SESPI
Tongji Hospital
Phase 2 Unknown